JPWO2020188466A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020188466A5 JPWO2020188466A5 JP2021556391A JP2021556391A JPWO2020188466A5 JP WO2020188466 A5 JPWO2020188466 A5 JP WO2020188466A5 JP 2021556391 A JP2021556391 A JP 2021556391A JP 2021556391 A JP2021556391 A JP 2021556391A JP WO2020188466 A5 JPWO2020188466 A5 JP WO2020188466A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- pediatric patient
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
当業者は、広い発明概念から逸脱することなく前述の実施形態に変更を行うことができることを理解するであろう。したがって、本発明は、開示された特定の実施形態に限定されるものではなく、具体的な説明によって定義された本発明の精神と範囲内の変更をカバーすることが意図されていることが理解される。
以下の態様を包含し得る。
［１］ それを必要とする小児患者の乾癬を治療する方法であって、安全かつ有効な量の抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体を含む医薬組成物を前記小児患者に投与することを含み、前記抗体が重鎖可変領域及び軽鎖可変領域を含み、前記重鎖可変領域が、配列番号１の相補性決定領域重鎖１（ＣＤＲＨ１）アミノ酸配列、配列番号２のＣＤＲＨ２アミノ酸配列、及び配列番号３のＣＤＲＨ３アミノ酸配列を含み、前記軽鎖可変領域が、配列番号４の相補性決定領域軽鎖１（ＣＤＲＬ１）アミノ酸配列、配列番号５のＣＤＲＬ２アミノ酸配列、及び配列番号６のＣＤＲＬ３アミノ酸配列を含み、前記小児患者が、少なくとも６歳かつ１２歳未満であり、治療後に０又は１の医師総合評価（ＰＧＡ）スコアを有すると識別され、及び／又は乾癬面積及び重症度指数スコア（ＰＡＳＩ）が少なくとも７５％、９０％又は１００％減少したと識別されることによる、前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体による治療に対する応答者である、方法。
［２］ 前記抗体が、前記小児患者に皮下投与される、請求項１に記載の方法。
［３］ 前記小児患者が、前記投与時に６０ｋｇ未満の体重を有し、前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、投与当たり、前記小児患者の体重に対して、約０．５ｍｇ／ｋｇ～１．０ｍｇ／ｋｇ、好ましくは０．７５ｍｇ／ｋｇの前記安全かつ有効な量で前記患者に皮下投与される、請求項２に記載の方法。
［４］ 前記小児患者が、前記投与時に６０ｋｇ～１００ｋｇの体重を有し、前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、投与当たり、約３５ｍｇ～５５ｍｇの前記安全かつ有効な量で、前記患者に皮下投与される、請求項２に記載の方法。
［５］ 前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、投与当たり、４５ｍｇで投与される、請求項４に記載の方法。
［６］ 前記小児患者が、前記投与時に１００ｋｇを超える体重を有し、前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、投与当たり、約８０ｍｇ～１００ｍｇの前記安全かつ有効な量で、前記患者に皮下投与される、請求項２に記載の方法。
［７］ 前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、投与当たり、９０ｍｇで投与される、請求項６に記載の方法。
［８］ 前記抗体が、配列番号７のアミノ酸配列を有する重鎖可変領域と、配列番号８のアミノ酸配列を有する軽鎖可変領域と、を含む、請求項１に記載の方法。
［９］ 前記抗体が、配列番号１０のアミノ酸配列を有する重鎖と、配列番号１１のアミノ酸配列を有する軽鎖と、を含む、請求項１に記載の方法。
［１０］ 前記安全かつ有効な量の前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、前記小児患者に繰り返し投与される、請求項１に記載の方法。
［１１］ 前記安全かつ有効な量の前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、前記治療の０週目及び４週目に前記小児患者に投与される、請求項１に記載の方法。
［１２］ 前記安全かつ有効な量の前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、４週目後１２週毎に、前記小児患者に更に投与される、請求項１１に記載の方法。
［１３］ 前記小児患者が、乾癬薬又は乾癬治療にナイーブである、請求項１に記載の方法。
［１４］ 前記小児患者が、局所剤、光線療法、非生物学的全身性薬剤、及び生物学的薬剤からなる群から選択される少なくとも１つの乾癬薬又は乾癬治療を受けたことがある、請求項１に記載の方法。
［１５］ 前記小児患者が、前記少なくとも１つの乾癬薬又は乾癬治療に応答性がないか、又は応答性が悪い、請求項１４に記載の方法。
［１６］ 前記小児患者が、局所剤に応答性がないか、又は応答性が悪い、請求項１５に記載の方法。
［１７］ 前記小児患者が、前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体による前記治療に対する応答者であり、前記治療の５２週目、２８週目又は１２週目までに０又は１の医師総合評価（ＰＧＡ）スコアを有すると識別される、請求項１に記載の方法。
［１８］ 前記小児患者が、前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体による前記治療に対する応答者であり、前記治療の５２週目、２８週目、又は１２週目までに前記乾癬面積及び重症度指数スコア（ＰＡＳＩ）が少なくとも７５％、９０％、又は１００％減少していると識別される、請求項１に記載の方法。
［１９］ 前記小児患者が、前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体による前記治療に対する応答者であり、前記治療の１２週目までに小児の皮膚科的生活の質指数（ＣＤＬＱＩ）のベースラインからの変化を有すると識別される、請求項１に記載の方法。
［２０］ 前記小児患者が、前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体の定常状態のトラフ血清濃度を有し、前記定常状態のトラフ血清濃度が、前記治療の５２週目、４０週目、又は２８週目までに達成される、請求項１に記載の方法。
［２１］ 前記定常状態のトラフ血清濃度が、前記治療の５２週目まで維持される、請求項２０に記載の方法。
［２２］ 前記抗ＩＬ－１２／２３ｐ４０抗体が、ウステキヌマブである、請求項１に記載の方法。
［２３］ 前記治療される乾癬が、中程度から重度の慢性プラーク乾癬である、請求項１に記載の方法。
［２４］ 前記治療される乾癬が、少なくとも３の医師総合評価（ＰＧＡ）スコア、少なくとも１２の乾癬面積及び重症度指数スコア（ＰＡＳＩ）、及び／又は少なくとも１０％の影響を受けた体表面積（ＢＳＡ）のパーセント、によって定義される重度の慢性プラーク乾癬である、請求項２３に記載の方法。
［２５］ 小児患者の重度の慢性プラーク乾癬を治療する方法であって、前記重度の慢性プラーク乾癬が、少なくとも３の医師総合評価（ＰＧＡ）スコア、少なくとも１２の乾癬面積及び重症度指数スコア（ＰＡＳＩ）、及び／又は少なくとも１０％の影響を受けた体表面積（ＢＳＡ）のパーセントによって定義され、前記方法が、前記小児患者に、安全かつ有効な量の抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体を皮下投与することを含み、前記抗体が、（ｉ）配列番号１の相補性決定領域重鎖１（ＣＤＲＨ１）アミノ酸配列、配列番号２のＣＤＲＨ２アミノ酸配列、及び配列番号３のＣＤＲＨ３アミノ酸配列を含む重鎖可変領域、並びに配列番号４の相補性決定領域軽鎖１（ＣＤＲＬ１）アミノ酸配列、配列番号５のＣＤＲＬ２アミノ酸配列、及び配列番号６のＣＤＲＬ３アミノ酸配列を含む軽鎖可変領域、（ｉｉ）配列番号７のアミノ酸配列を有する重鎖可変領域、及び配列番号８のアミノ酸配列を有する軽鎖可変領域、又は（ｉｉｉ）配列番号１０のアミノ酸配列を有する重鎖、及び配列番号１１のアミノ酸配列を有する軽鎖、を含む重鎖可変領域を含み、前記安全かつ有効な量の前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、
１）前記小児患者が前記投与時に６０ｋｇ未満の体重を有する場合、投与当たり、前記小児患者の体重に対し、約０．５ｍｇ／ｋｇ～１．０ｍｇ／ｋｇ、好ましくは０．７５ｍｇ／ｋｇ、
２）前記小児患者が前記投与時に６０ｋｇ～１００ｋｇの体重を有する場合、投与当たり、約３５ｍｇ～５５ｍｇ、好ましくは約４５ｍｇ、又は
３）前記小児患者が前記投与時に１００ｋｇを超える体重を有する場合、投与当たり、約８０ｍｇ～１００ｍｇ、好ましくは９０ｍｇ、である、
方法。
Those skilled in the art will appreciate that changes can be made to the above-described embodiments without departing from the broad inventive concept. It is therefore understood that the invention is not limited to the particular embodiments disclosed, but is intended to cover modifications within the spirit and scope of the invention defined by the specific description. be done.
The following aspects may be included.
[1] A method of treating psoriasis in a pediatric patient in need thereof comprising administering to said pediatric patient a pharmaceutical composition comprising a safe and effective amount of an anti-IL-12/IL-23p40 antibody , the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO: 1, the CDRH2 amino acid sequence of SEQ ID NO: 2, and the sequence 3, wherein said light chain variable region comprises the complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO: 4, the CDRL2 amino acid sequence of SEQ ID NO: 5, and the CDRL3 amino acid sequence of SEQ ID NO: 6. wherein said pediatric patient is at least 6 years old and less than 12 years old, is identified as having a Physician Global Assessment (PGA) score of 0 or 1 after treatment, and/or has a Psoriasis Area and Severity Index score (PASI) is a responder to treatment with said anti-IL-12/IL-23p40 antibody by being identified as being reduced by at least 75%, 90% or 100%.
[2] The method of Claim 1, wherein said antibody is administered subcutaneously to said pediatric patient.
[3] the pediatric patient has a body weight of less than 60 kg at the time of administration, and the anti-IL-12/IL-23p40 antibody is about 0.5 mg/kg to the body weight of the pediatric patient per administration; 3. The method of claim 2, wherein said safe and effective amount of 1.0 mg/kg, preferably 0.75 mg/kg is administered subcutaneously to said patient.
[4] said pediatric patient has a body weight of 60 kg to 100 kg at said administration, and said anti-IL-12/IL-23p40 antibody is administered in said safe and effective amount of about 35 mg to 55 mg per administration; 3. The method of claim 2, wherein the method is administered subcutaneously to
[5] The method of claim 4, wherein said anti-IL-12/IL-23p40 antibody is administered at 45 mg per administration.
[6] said pediatric patient has a body weight greater than 100 kg at said administration, and said anti-IL-12/IL-23p40 antibody is administered to said patient in said safe and effective amount of about 80 mg to 100 mg per administration; 3. The method of claim 2, administered subcutaneously.
[7] The method of claim 6, wherein the anti-IL-12/IL-23p40 antibody is administered at 90 mg per administration.
[8] The method of [1], wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO:7 and a light chain variable region having the amino acid sequence of SEQ ID NO:8.
[9] The method of Claim 1, wherein the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO:10 and a light chain having the amino acid sequence of SEQ ID NO:11.
10. The method of claim 1, wherein said safe and effective amount of said anti-IL-12/IL-23p40 antibody is repeatedly administered to said pediatric patient.
11. The method of claim 1, wherein said safe and effective amount of said anti-IL-12/IL-23p40 antibody is administered to said pediatric patient at weeks 0 and 4 of said treatment.
12. The method of claim 11, wherein said safe and effective amount of said anti-IL-12/IL-23p40 antibody is further administered to said pediatric patient every 12 weeks after 4 weeks.
13. The method of claim 1, wherein the pediatric patient is naive to psoriasis drugs or psoriasis treatments.
[14] wherein the pediatric patient has received at least one psoriasis drug or psoriasis treatment selected from the group consisting of topical agents, phototherapy, non-biologic systemic agents, and biological agents; Item 1. The method according to item 1.
15. The method of Claim 14, wherein said pediatric patient is unresponsive or poorly responsive to said at least one psoriasis drug or psoriasis treatment.
[16] The method of Claim 15, wherein the pediatric patient is unresponsive or poorly responsive to topical agents.
[17] said pediatric patient is a responder to said treatment with said anti-IL-12/IL-23p40 antibody and has a Physician Global Rating of 0 or 1 by Week 52, Week 28 or Week 12 of said treatment 2. The method of claim 1, identified as having a (PGA) score.
[18] said pediatric patient is a responder to said treatment with said anti-IL-12/IL-23p40 antibody and said psoriasis area and severity by week 52, week 28, or week 12 of said treatment; 2. The method of claim 1, wherein the index score (PASI) is identified as decreasing by at least 75%, 90%, or 100%.
[19] said pediatric patient is a responder to said treatment with said anti-IL-12/IL-23p40 antibody and has a baseline Pediatric Dermatological Quality of Life Index (CDLQI) by week 12 of said treatment; 2. The method of claim 1, identified as having a variation from .
[20] said pediatric patient has a steady-state trough serum concentration of said anti-IL-12/IL-23p40 antibody, wherein said steady-state trough serum concentration is at week 52, week 40, or of said treatment; 2. The method of claim 1, achieved by week 28.
[21] The method of Claim 20, wherein said steady-state trough serum concentration is maintained up to week 52 of said treatment.
[22] The method of claim 1, wherein the anti-IL-12/23p40 antibody is ustekinumab.
23. The method of claim 1, wherein the psoriasis to be treated is moderate to severe chronic plaque psoriasis.
[24] The treated psoriasis has a Physician Global Assessment (PGA) score of at least 3, a Psoriasis Area and Severity Index (PASI) score of at least 12, and/or body surface area affected (BSA) of at least 10% 24. The method of claim 23, wherein severe chronic plaque psoriasis is defined by the percentage of
[25] A method of treating severe chronic plaque psoriasis in a pediatric patient, wherein said severe chronic plaque psoriasis has a Physician Global Assessment (PGA) score of at least 3, a Psoriasis Area and Severity Index score (PASI) of at least 12 ), and/or by a percent body surface area (BSA) affected of at least 10%, wherein the method includes subcutaneously administering to the pediatric patient a safe and effective amount of an anti-IL-12/IL-23p40 antibody. wherein the antibody comprises (i) a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1, a CDRH2 amino acid sequence of SEQ ID NO:2, and a CDRH3 amino acid sequence of SEQ ID NO:3. (ii) a light chain variable region comprising a variable region and a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4, a CDRL2 amino acid sequence of SEQ ID NO:5, and a CDRL3 amino acid sequence of SEQ ID NO:6; and a light chain variable region having the amino acid sequence of SEQ ID NO:8, or (iii) a heavy chain having the amino acid sequence of SEQ ID NO:10 and a light chain having the amino acid sequence of SEQ ID NO:11 wherein said safe and effective amount of said anti-IL-12/IL-23p40 antibody comprises:
1) about 0.5 mg/kg to 1.0 mg/kg, preferably 0.75 mg/kg, of the pediatric patient's body weight per administration, if the pediatric patient has a weight of less than 60 kg at the time of administration;
2) about 35 mg to 55 mg, preferably about 45 mg per administration, when said pediatric patient has a body weight of 60 kg to 100 kg at said administration, or
3) about 80 mg to 100 mg, preferably 90 mg per dose, if said pediatric patient weighs more than 100 kg at said dose;
Method.
Claims (25)
前記医薬組成物が、安全かつ有効な量の抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体を含み、
前記方法が、前記医薬組成物を前記小児患者に投与することを含み、前記抗体が重鎖可変領域及び軽鎖可変領域を含み、前記重鎖可変領域が、配列番号１の相補性決定領域重鎖１（ＣＤＲＨ１）アミノ酸配列、配列番号２のＣＤＲＨ２アミノ酸配列、及び配列番号３のＣＤＲＨ３アミノ酸配列を含み、前記軽鎖可変領域が、配列番号４の相補性決定領域軽鎖１（ＣＤＲＬ１）アミノ酸配列、配列番号５のＣＤＲＬ２アミノ酸配列、及び配列番号６のＣＤＲＬ３アミノ酸配列を含み、前記小児患者が、少なくとも６歳かつ１２歳未満であり、治療後に０又は１の医師総合評価（ＰＧＡ）スコアを有すると識別され、及び／又は乾癬面積及び重症度指数スコア（ＰＡＳＩ）が少なくとも７５％、９０％又は１００％減少したと識別されることによる、前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体による治療に対する応答者である、医薬組成物。 A pharmaceutical composition for use in a method of treating psoriasis in a pediatric patient in need thereof comprising:
said pharmaceutical composition comprises a safe and effective amount of an anti-IL-12/IL-23p40 antibody;
The method comprises administering the pharmaceutical composition to the pediatric patient, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the complementarity determining region heavy region of SEQ ID NO:1. a chain 1 (CDRH1) amino acid sequence, a CDRH2 amino acid sequence of SEQ ID NO:2, and a CDRH3 amino acid sequence of SEQ ID NO:3, wherein said light chain variable region comprises the complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4 , the CDRL2 amino acid sequence of SEQ ID NO:5, and the CDRL3 amino acid sequence of SEQ ID NO:6, wherein the pediatric patient is at least 6 years old and less than 12 years old and has a Physician Global Assessment (PGA) score of 0 or 1 after treatment. response to treatment with said anti-IL-12/IL-23p40 antibody by being identified as having at least a 75%, 90% or 100% reduction in Psoriasis Area and Severity Index Score (PASI) A pharmaceutical composition .
前記医薬組成物が抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体を含み、
前記重度の慢性プラーク乾癬が、少なくとも３の医師総合評価（ＰＧＡ）スコア、少なくとも１２の乾癬面積及び重症度指数スコア（ＰＡＳＩ）、及び／又は少なくとも１０％の影響を受けた体表面積（ＢＳＡ）のパーセントによって定義され、
前記方法が、前記小児患者に、安全かつ有効な量の抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体を皮下投与することを含み、前記抗体が、（ｉ）配列番号１の相補性決定領域重鎖１（ＣＤＲＨ１）アミノ酸配列、配列番号２のＣＤＲＨ２アミノ酸配列、及び配列番号３のＣＤＲＨ３アミノ酸配列を含む重鎖可変領域、並びに配列番号４の相補性決定領域軽鎖１（ＣＤＲＬ１）アミノ酸配列、配列番号５のＣＤＲＬ２アミノ酸配列、及び配列番号６のＣＤＲＬ３アミノ酸配列を含む軽鎖可変領域、（ｉｉ）配列番号７のアミノ酸配列を有する重鎖可変領域、及び配列番号８のアミノ酸配列を有する軽鎖可変領域、又は（ｉｉｉ）配列番号１０のアミノ酸配列を有する重鎖、及び配列番号１１のアミノ酸配列を有する軽鎖、を含み、前記安全かつ有効な量の前記抗ＩＬ－１２／ＩＬ－２３ｐ４０抗体が、
１）前記小児患者が前記投与時に６０ｋｇ未満の体重を有する場合、投与当たり、前記小児患者の体重に対し、約０．５ｍｇ／ｋｇ～１．０ｍｇ／ｋｇ、好ましくは０．７５ｍｇ／ｋｇ、
２）前記小児患者が前記投与時に６０ｋｇ～１００ｋｇの体重を有する場合、投与当たり、約３５ｍｇ～５５ｍｇ、好ましくは約４５ｍｇ、又は
３）前記小児患者が前記投与時に１００ｋｇを超える体重を有する場合、投与当たり、約８０ｍｇ～１００ｍｇ、好ましくは９０ｍｇ、である、
医薬組成物。
A pharmaceutical composition for use in a method of treating severe chronic plaque psoriasis in a pediatric patient comprising:
wherein said pharmaceutical composition comprises an anti-IL-12/IL-23p40 antibody;
said severe chronic plaque psoriasis has a Physician Global Assessment (PGA) score of at least 3, a Psoriasis Area and Severity Index score (PASI) of at least 12, and/or a body surface area affected (BSA) of at least 10% defined by a percentage,
The method comprises subcutaneously administering to the pediatric patient a safe and effective amount of an anti-IL-12/IL-23p40 antibody, wherein the antibody comprises (i) the complementarity determining region heavy chain 1 of SEQ ID NO: 1 a heavy chain variable region comprising the (CDRH1) amino acid sequence , the CDRH2 amino acid sequence of SEQ ID NO:2, and the CDRH3 amino acid sequence of SEQ ID NO:3, and the complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4, SEQ ID NO:5 and the CDRL3 amino acid sequence of SEQ ID NO:6, (ii) a heavy chain variable region having the amino acid sequence of SEQ ID NO:7 and a light chain variable region having the amino acid sequence of SEQ ID NO:8; or (iii) a heavy chain having the amino acid sequence of SEQ ID NO: 10 and a light chain having the amino acid sequence of SEQ ID NO: 11, wherein the safe and effective amount of the anti-IL-12/IL-23p40 antibody is
1) about 0.5 mg/kg to 1.0 mg/kg, preferably 0.75 mg/kg, of the pediatric patient's body weight per administration, if the pediatric patient has a weight of less than 60 kg at the time of administration;
2) about 35 mg to 55 mg, preferably about 45 mg per dose, if said pediatric patient weighs between 60 kg and 100 kg at said administration; or 3) if said pediatric patient weighs more than 100 kg at said dose. is about 80 mg to 100 mg, preferably 90 mg, per
pharmaceutical composition .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819860P | 2019-03-18 | 2019-03-18 | |
| US62/819,860 | 2019-03-18 | ||
| PCT/IB2020/052387 WO2020188466A1 (en) | 2019-03-18 | 2020-03-16 | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526493A JP2022526493A (en) | 2022-05-25 |
| JPWO2020188466A5 true JPWO2020188466A5 (en) | 2023-03-27 |
Family
ID=72519087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556391A Pending JP2022526493A (en) | 2019-03-18 | 2020-03-16 | Treatment of Psoriasis in Pediatric Subjects Using Anti-IL12 / IL23 Antibodies |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200331996A1 (en) |
| EP (1) | EP3941934A4 (en) |
| JP (1) | JP2022526493A (en) |
| KR (1) | KR20210141583A (en) |
| CN (1) | CN113853385A (en) |
| AU (1) | AU2020243588A1 (en) |
| BR (1) | BR112021018441A2 (en) |
| CA (1) | CA3134079A1 (en) |
| EA (1) | EA202192459A1 (en) |
| IL (1) | IL286387A (en) |
| MA (1) | MA55383A (en) |
| MX (1) | MX2021011328A (en) |
| WO (1) | WO2020188466A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4188443A4 (en) * | 2020-07-30 | 2024-09-18 | Janssen Biotech Inc | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3590766T (en) | 1985-03-30 | 1987-04-23 | ||
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (en) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | METHOD FOR DECODING BINARY SIGNALS AND VITERBI DECODERS AND APPLICATIONS |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| DE3852304T3 (en) | 1987-03-02 | 1999-07-01 | Enzon Labs Inc., Piscataway, N.J. | Organism as carrier for "Single Chain Antibody Domain (SCAD)". |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
| JP2980626B2 (en) | 1988-01-11 | 1999-11-22 | ゾーマ・コーポレーション | Novel plasmid vector containing pectate lyase signal sequence |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US4987893A (en) | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
| KR0184860B1 (en) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | Single domain ligands receptors comprising said ligands methods for their production and use of said ligands |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| EP0478627A4 (en) | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| JP3127158B2 (en) | 1989-10-05 | 2001-01-22 | オプテイン，インコーポレイティド | Cell-free synthesis and isolation of novel genes and polypeptides |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0600866B1 (en) | 1990-06-01 | 1997-12-03 | Chiron Corporation | Compositions and methods for identifying biologically active molecules |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| EP0544809B1 (en) | 1990-08-24 | 1998-12-16 | Ixsys, Inc. | Methods of synthesizing oligonucleotides with random codons |
| KR100272077B1 (en) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DK0564531T3 (en) | 1990-12-03 | 1998-09-28 | Genentech Inc | Enrichment procedure for variant proteins with altered binding properties |
| NZ241119A (en) | 1990-12-20 | 1993-06-25 | Ixsys Inc | Manipulating nucleic acid to optimize the binding characteristics of the encoded binding protein |
| IE920562A1 (en) | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
| WO1992016221A1 (en) | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
| CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| ES2227512T3 (en) | 1991-12-02 | 2005-04-01 | Medical Research Council | PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO. |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| DE69333823T2 (en) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | METHOD FOR PRODUCING MEMBERS OF SPECIFIC BINDING SAVINGS |
| US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| AU6132994A (en) | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
| JPH08509612A (en) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | Transgenic non-human animal capable of producing heterologous antibody |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| JPH09506508A (en) | 1993-12-03 | 1997-06-30 | メディカル リサーチ カウンシル | Recombinant binding proteins and peptides |
| SE9304060D0 (en) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Methods to select specific bacteriophages |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| EP0787185A2 (en) | 1994-10-20 | 1997-08-06 | MorphoSys AG | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| ATE219517T1 (en) | 1995-08-18 | 2002-07-15 | Morphosys Ag | PROTEIN/(POLY)PEPTIDE LIBRARIES |
| US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| DE19624387C2 (en) | 1996-06-19 | 1999-08-19 | Hatz Motoren | Cold start device |
| GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | Transdermal delivery system |
| EP1007967A2 (en) | 1997-08-04 | 2000-06-14 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
| ATE239447T1 (en) | 1997-09-29 | 2003-05-15 | Inhale Therapeutic Syst | STABILIZED PREPARATIONS USABLE IN NEBULIZERS |
| EP1071700B1 (en) | 1998-04-20 | 2010-02-17 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| BR0008758A (en) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variants of parental polypeptides with altered effector function, polypeptides, isolated nucleic acid composition, vector, host cell, method for producing a polypeptide variant, method for treating a disorder in mammals and method for producing a variant fc region |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
| NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| EP1623011B1 (en) | 2003-05-09 | 2013-01-02 | Janssen Biotech, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
| CN101379085B (en) | 2005-06-30 | 2013-03-27 | Abbvie公司 | IL-12/P40 binding proteins |
| WO2013009535A1 (en) * | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors |
| SG10201804954UA (en) * | 2013-03-15 | 2018-07-30 | Amgen Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| KR20180063127A (en) * | 2015-09-17 | 2018-06-11 | 암젠 인크 | Prediction of Clinical Response to IL23-Antagonists Using IL23 Pathway Biomarkers |
| US10765724B2 (en) * | 2016-03-29 | 2020-09-08 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody |
-
2020
- 2020-03-16 EP EP20774332.9A patent/EP3941934A4/en active Pending
- 2020-03-16 MA MA055383A patent/MA55383A/en unknown
- 2020-03-16 KR KR1020217033377A patent/KR20210141583A/en active Search and Examination
- 2020-03-16 MX MX2021011328A patent/MX2021011328A/en unknown
- 2020-03-16 CA CA3134079A patent/CA3134079A1/en active Pending
- 2020-03-16 JP JP2021556391A patent/JP2022526493A/en active Pending
- 2020-03-16 US US16/819,629 patent/US20200331996A1/en not_active Abandoned
- 2020-03-16 WO PCT/IB2020/052387 patent/WO2020188466A1/en unknown
- 2020-03-16 BR BR112021018441A patent/BR112021018441A2/en unknown
- 2020-03-16 AU AU2020243588A patent/AU2020243588A1/en active Pending
- 2020-03-16 EA EA202192459A patent/EA202192459A1/en unknown
- 2020-03-16 CN CN202080037066.1A patent/CN113853385A/en active Pending
-
2021
- 2021-09-14 IL IL286387A patent/IL286387A/en unknown
-
2022
- 2022-09-13 US US17/931,633 patent/US20230014839A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523295A5 (en) | ||
| JP6654967B2 (en) | Pharmaceutical composition for preventing and / or treating atopic dermatitis, comprising an IL-31 antagonist as an active ingredient | |
| JP2020502261A5 (en) | ||
| JP2022126791A (en) | Methods of treating new-onset plaque-type psoriasis using il-17 antagonists | |
| JP2021502349A5 (en) | ||
| JP2020500152A5 (en) | ||
| IL310216A (en) | Methods of treating crohn's disease with anti-il23 specific antibody | |
| US20230331834A1 (en) | Method of treating tendinopathy using interleukin-17 (il-17) | |
| JP2020535149A5 (en) | ||
| WO2021101975A1 (en) | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies | |
| JP7410256B2 (en) | Pan-ELR+CXC chemokine antibody for the treatment of hidradenitis suppurativa | |
| JPWO2020188466A5 (en) | ||
| JP5954916B1 (en) | A pharmaceutical composition for preventing and / or treating atopic dermatitis, comprising an IL-31 antagonist as an active ingredient | |
| JPWO2019171252A5 (en) | ||
| JPWO2020245766A5 (en) | ||
| US20230303678A1 (en) | Methods for treatment of subjects with plaque psoriasis of the scalp | |
| WO2016189491A1 (en) | Novel formulation | |
| JPWO2020012244A5 (en) | ||
| IL312778A (en) | Methods of treating crohn's disease with anti-il23 specific antibody | |
| WO2021111377A2 (en) | Methods of treating lichen planus using interleukin-17 (il-17) antagonists | |
| JPWO2021224823A5 (en) | ||
| KR20210140780A (en) | Methods of Treating a Subject with Psoriatic Arthritis | |
| JPWO2019135363A1 (en) | A therapeutic agent for diseases mainly involving tendon synovial lesions | |
| JPWO2020128864A5 (en) | ||
| JPWO2020212874A5 (en) |